Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 10/20 | 1.00 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828248 | 1.00 | CFTR (1.00) | CFTRBAZ2BNPC1RAB9AKMT2A | |
| SCHEMBL23828252 | 0.88 | CFTR (0.79) | CFTRBAZ2BNPC1KMT2AUSP2 | |
| SCHEMBL31020955 | 0.88 | CFTR (0.79) | CFTRBAZ2BNPC1KMT2AUSP2 | |
| SCHEMBL23828297 | 0.86 | CFTR (1.00) | CFTRBAZ2BNPC1RAB9AKMT2A | |
| SCHEMBL30570561 | 0.86 | CFTR (1.00) | CFTRBAZ2BNPC1RAB9AKMT2A | |
| SCHEMBL29171356 | 0.77 | BAZ2B (0.82) | CFTRBAZ2BKDRUSP2CYP1A2 | |
| SCHEMBL23828266 | 0.76 | CFTR (0.65) | CFTRBAZ2BKDRUSP2CYP1A2 | |
| SCHEMBL30570535 | 0.76 | CFTR (0.65) | CFTRBAZ2BKDRUSP2CYP1A2 | |
| SCHEMBL23828254 | 0.76 | CFTR (0.75) | CFTRBAZ2BKDRUSP2CYP1A2 | |
| SCHEMBL17447456 | 0.74 | BAZ2B (0.76) | CFTRBAZ2BKDRUSP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC5 | CFTR 1/4885BAZ2B 4498/4885NPC1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.